Barinthus Biotherapeutics (BRNS) Equity Average (2020 - 2026)

Barinthus Biotherapeutics has reported Equity Average for 7 years, with the latest figure at $70.3 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 42.78% year-over-year to $70.3 million; the trailing twelve-month figure through Mar 2026 stood at $70.3 million (down 42.78% YoY), and the FY2025 full-year result was $102.2 million, down 35.56% from the prior year.
• Equity Average for Q1 2026 stood at $70.3 million, down from $79.4 million in the prior quarter.
• The five-year high for Equity Average was $254.0 million in Q2 2022, with the low at $70.3 million in Q1 2026.
• Historically, Equity Average has averaged $175.5 million across 5 years, with a median of $179.5 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average jumped 663.5% — and 2025, when it plunged 45.18%.
• Barinthus Biotherapeutics' Equity Average stood at $243.7 million in 2022, then slipped by 21.49% to $191.3 million in 2023, then fell by 24.31% to $144.8 million in 2024, then sank by 45.18% to $79.4 million in 2025, then fell by 11.44% to $70.3 million in 2026.
• The last three Equity Average figures came in at $70.3 million (Q1 2026), $79.4 million (Q4 2025), and $93.5 million (Q3 2025), per Business Quant data.